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Abstract
Background: Clinical trials on osteoarthritis (OA) flare-ups treatment usually focus only on
objective measures of health status, albeit recent literature suggestions on the importance of
patients' subjectivity. Aim of the study was to evaluate the effects of OA and of its different types
of medical treatment(s) on Health Related Quality of Life (HRQoL) in terms of both subjective
satisfaction and functional status.
Methods: An observational study on prospective data collected from the Evaluation of Quality of
life in OA (EQuO) clinical trial (April 1999-November 2000) was conducted; outpatients from 70
participating centers (Orthopedy or Rheumatology Departments in Italy) with a diagnosis of OA
of the hip or knee were consecutively enrolled. Patients were observed at OA flare-ups (baseline)
and at follow up 4 weeks after treatment. Patients' objective and subjective HRQoL were assessed
by means of the SF-36 and the Satisfaction Profile (SAT-P, which focuses on subjective satisfaction);
Present Pain at baseline and Pain Relief at follow up were also evaluated.
Results:  Among the 1323 patients, 1138 (86%) were prescribed one drug/treatment of
osteoarthritis, 169 (13%) 2 drugs/treatments, and 16 (1%) 3 drugs/treatments; most of treatments
involved the prescription of NSAIDs; non-coxib, COX2 selective NSAIDs were prescribed in
about 50% of patients. Follow-up visits were performed after 29.0 days on average (± 7.69 SD). For
all SF-36 domains, all SAT-P items and factors, the differences between baseline and follow up
scores resulted statistically significant (p < 0.001), enlighting an improvement both in health status
and in subjective HRQoL.
Conclusion: Besides the classic health status measures, the assessment of patients' subjective
satisfaction provides important clues on treatments efficacy of OA within the patient-centered
medicine model. In clinical practice this could lead to a better doctor-patient communication and
to higher levels of treatment adherence.
Background
The impact of osteoarthritis (OA) on patient's functional
levels is well known [1-3]. Pain and physical limitations
constitute difficulties patients have to deal with [4,5] and
require long term pharmacological treatment and physi-
cal therapies.
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Usually OA affects elderly people, and is one of the main
causes of physical disability. In OA patients, Health
Related Quality of Life (HRQoL) and activities of daily liv-
ing are negatively affected. Significant work disability,
reduced ability to deal with household duties and sleep
disorders are reported in patients with symptoms of OA
flare-ups, together with dysfunctions in the areas of ambu-
lation, body-care and movement (in terms of perceived
health status), and emotional behaviour (in terms of per-
ceived psychological functioning) [1,2,4-8].
As a chronic condition, the impact of OA has been studied
mainly focusing on its consequences on health status.
Similarly, treatment efficacy is assessed within the context
of health status and/or symptomatology in many clinical
trials [6,7,9-12]. However, health status and symptoma-
tology can be considered only two components of HRQoL
[13] and little is known about the impact of OA and its
treatments on patient's subjective perspective, in spite of
increasing attention on this topic [14-19].
In literature, HRQoL refers to patients' appraisals of their
current levels of functioning and satisfaction, compared
to what they perceive to be ideal [20]. HRQoL assessment
allows a subject to express his or her ability to perform
daily activities across many domains which include phys-
ical, social and cognitive functioning, role activities and
emotional wellbeing. Besides, "...how a subject feels
about the performace of each of those activities may be
assessed separately by measuring satisfaction for each
domain." [21]. The subjective implications of HRQoL,
within the context of patient centred medicine, have been
already stressed by suggestions from recent reliable scien-
tific literature [15,17-24].
The aim of the present study is to evaluate the effects of
OA and of its different types of medical treatment(s) on
HRQoL in terms of both subjective satisfaction and func-
tional status.
Methods
Patient population and procedure
Data from collaborating, educated outpatients aged 50–
80 years with a diagnosis of OA of the hip or knee accord-
ing to the criteria of the American College of Rheumatol-
ogy [25] were collected in this observational, prospective
study.
Outpatients (n = 1340) were consecutively enrolled in 70
Italian participating centers (Orthopedy or Rheumatology
Departments, listed in Appendix A [see additional file])
from April 1999 to November 2000. 147 patients with-
drawn OA treatment before follow-up visit.
All patients signed an informed consent in which the pur-
poses of the study (HRQoL assessment and treatment effi-
cacy, as primary and secondary outcomes respectively)
were clearly stated. Approval for this research was
obtained by the ethics committee, patients did not receive
any remuneration for their participation.
Patients with concomitant osteoarticular disorders,
impairment of motor function not due to OA of the hip
or knee, concomitant systemic disease(s) affecting
HRQoL or requiring NSAIDs/steroids use on a regular
basis were not included into the study, in order to avoid
biases in the results due to treatments other than OA
treatments.
Patients were observed at OA flare-ups, when attending
for a visit (baseline) and at follow up 4 weeks after treat-
ment. According to the observational design of this trial,
no "study treatments" were assigned to patients, but any
drug(s)/medical treatment(s) considered by the physician
as adequate to the patient's clinical condition was freely
prescribed; therefore patients were not previously rand-
omized to treatment.
During both visits, patients were administered the follow-
ing: the Visual Analogue Scale (VAS) [26] on Present Pain
(baseline) or on Pain Relief (follow up); the Medical Out-
comes Study Short-Form 36 Health Status Survey (SF-36)
[27] in its validated Italian version [28,29] and the Satis-
faction Profile (SAT-P) [30].
Moreover, at follow up, the global assessments of efficacy
and tolerability of the medical treatment(s) prescribed for
OA flare ups (expressed by the patient and by the physi-
cian according to a 4 point semi-quantitative rating scale:
excellent – good – moderate – poor) were collected. Side
effects to this/these treatment(s), if any, were registered as
well.
The assessment procedure was standardized for all the
participating centres. During the visit patients were
invited to compile alone all the questionnaires and rating
scales, only if required patients were assisted by a trained
health professional.
Self-reporting bias in HRQoL improvements was kept
under control by the assessment procedure and by the
adoption of valid and reliable questionnaires.
Measures
Visual Analogue Scale
The VAS is perhaps the most widely used instrument for
the measurement of pain intensity. The classic version of
the VAS was administered: 10 centimeter line, horizontal.
"It is a simple, robust, sensitive, and reproducibleHealth and Quality of Life Outcomes 2005, 3:14 http://www.hqlo.com/content/3/1/14
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instrument that enables a patient to express the severity of
his pain in such a way that it can be given a numerical
value." [26] Its psychometric properties and its utility in
clinical trials have been confirmed [2,8,31,32]. VAS on
Present Pain ranged from "no pain" to "the worst pain
possible"; VAS on Pain Relief ranged from "no pain relief"
to "the maximum pain relief". Scores ranged from 0 to
100.
SF-36
The SF-36 is a well known self-administered and generic
health status measure which encompasses 8 domains
related to daily life activities: physical functioning, role
limitations due to physical problems, role limitations due
to emotional problems, vitality, bodily pain, social func-
tioning, mental health and general health perception [33-
35]. Each domain scores from 0 (lowest level of function-
ing) to 100 (highest level of functioning). The instrument
has been extensively validated within the Medical Out-
come Study [33] and in other settings [34].
Satisfaction Profile
The SAT-P is a self-administered, generic questionnaire
which provides a satisfaction profile in daily life and can
be considered as an indicator of subjective QoL. Satisfac-
tion can be defined as the cognitive product of the com-
parison between ideal life and reality, and can therefore
be quantitatively measured. The subject is asked to evalu-
ate his/her satisfaction about 32 life aspects with reference
to the last month (on 32 10 cm horizontal VAS) inde-
pendently of his/her objective health status (for example:
"How satisfied have you been in the last month with your
Resistance to physical fatigue?"; "How satisfied...with
your Mood?"; "How satisfied...with your Emotional sta-
bility?"). It provides 32 individual scores and 5 factor
scores, all ranging from 0 (lowest level of satisfaction) to
100 (highest level of satisfaction). Together with its ability
to detect patient's subjective satisfaction, the SAT-P
addresses some aspects of daily life which are not
included in SF-36 items (i.e. sleep, sexual life, quality of
couple relationship, eating, self-confidence, resistance to
stress, etc.). Its psychometric properties and clinical utility
have been confirmed [30,36,37].
Statistical analyses
Sociodemographic data and clinical values were analysed
by means of descriptive statistics. Since the incidence of
withdrawals resulted low, analyses were performed on
complete cases and no solutions for handling missing
data was adopted.
Baseline and follow-up of SF-36 and SAT-P item and fac-
tor scores were compared by means of Analusis of Covar-
iance (ANCOVA). Moreover, ANCOVAs were adopted in
order to evaluate the impact of clinical variables on SF-36
and SAT-P factor delta scores (calculated subtracting the
follow-up scores from baseline scores). The variables
included into the models were: age, gender, body weight,
OA localization (hip, knee, or both), VAS Present Pain,
presence of concomitant disease(s), type of treatment
(COX2 selective NSAIDs vs. other treatments). Results
were summarized using mean ± SE for continuous varia-
bles and frequency (absolute and percent) for categorical
variables. All p values are two-tailed and p < .05 was con-
sidered statistically significant. All computations were car-
ried-out by resorting to SAS 8.0 procedures.
Results
Patients demographic and clinical characteristics (OA
localization (hip/knee/both), VAS Present Pain, type of
medical treatment(s) of OA flare-ups, concomitant dis-
eases and treatments are shown in Table 1. Patients' base-
line VAS Present Pain resulted consistent with a clinical
condition of moderate to severe rheumatic disease.
The most frequent concomitant diseases were: hyperten-
sion (19.1%), metabolic and nutritional disorders
(9.2%), muscoloskeletal, connective tissue and bone dis-
orders (8.2%) and gastrointestinal system disorders
(4.3%). The most frequently prescribed concomitant
treatments were: cardiologic drugs (9.7%) and antihyper-
tensive (9.4%), antidiabetic drugs (8.4%), antithrombotic
Table 1: Patients' characteristics
Gender (F/M) 795/528
Age (years, mean ± SD) 64.4 ± 10.3
Marital status:
Single, n (%) 72 (5.4)
Married, n (%) 922 (69.7)
Widowed, n (%) 220 (16.6)
Separated/divorced, n (%) 13 (1.0)
Missing, n(%) 96 (7.3)
Educational level:
Primary school, n (%) 548 (41.4)
Junior high school, n (%) 325 (24.6)
Senior high school, n (%) 280 (21.2)
Degree/Master/PhD, n (%) 103 (7.7)
Missing, n(%) 67 (5.1)
Employment status:
Employed, n (%) 434 (32.8)
Retired, n (%) 550 (41.6)
Housewife, n (%) 288 (21.8)
Missing, n (%) 51 (3.8)
Body weight (kg, mean ± SD) 73.4 ± 11.0
OA localization:
Knee, n (%) 658 (49.7)
Hip, n (%) 463 (35.1)
Knee + hip, n (%) 202 (15.2)
VAS Present Pain (mm, mean ± SD) 67.7 ± 17.0
Concomitant diseases, n (%) 632 (47.8)
Concomitant treatments, n (%) 444 (33.6)Health and Quality of Life Outcomes 2005, 3:14 http://www.hqlo.com/content/3/1/14
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agents (4.5%), antiacids (6.7%), sedatives (4.8%). 1138
patients (86%) were prescribed one drug/treatment of
OA, 169 patients (13%) 2 drugs/treatments, and 16
patients (1%) received 3 drugs/treatments. Most of treat-
ments involved the prescription of NSAIDs; non-coxib,
COX2 selective NSAIDs (nimesulide betadex and
nimesulide, the only two COX2 selective NSAIDs availa-
ble in Italy at the time of this study) were prescribed in
about 50% of patients (Table 2).
Follow-up visits were performed after 29.0 days on aver-
age (± 7.69 SD). Only a small number of patients (17;
1.2%) did not attend follow-up visit.
HRQoL assessment: SF-36
For all SF-36 domains, the difference between baseline
and follow up scores resulted statistically significant (p <
0.001) (Table 3).
Baseline Present Pain was associated with almost all the
SF-36 domains (Table 4). The presence of concomitant
disease(s) resulted in a statistically significant association
with 4 domains: Role Physical, Bodily Pain, General
Health, Social Functioning. The type of OA treatment was
associated with Physical Functioning and Bodily Pain. OA
localization and age was associated with only one
domain: Physical Functioning and Role Physical respec-
tively. Gender and body weight did not correlate with any
SF-36 domain.
HRQoL assessment: SAT-P factors
All the differences between baseline and follow up SAT-P
factor scores were statistically significant (p < 0.001)
(Table 5).
Baseline pain was significantly associated with all SAT-P
factors (Table 6). The presence of concomitant disease(s)
was in a statistically significant association with 3 out of 5
factors: Psychological functioning, Sleep-Eating-Leisure,
Social functioning. OA treatment was associated with the
factor Sleep-Eating-Leisure.
HRQoL assessment: SAT-P items
Figure 1 shows the graphic representation of baseline and
follow up SAT-P item scores. All the differences were sta-
tistically significant (p < 0.001).
Clinical outcome of OA treatment: Efficacy and 
Tolerability
At follow-up, mean VAS Pain Relief was 61.1 mm (± 24.3
SD).
In 65% of cases treatment efficacy was evaluated as good
or excellent by patients themselves, in 67% of cases it was
evaluated as good or excellent by physicians. In 81% of
cases treatment tolerability was evaluated as good or
excellent by patients themselves, in 84% of cases it was
evaluated as good or excellent by physicians. It was evalu-
ated as poor in 7% and 6% of cases respectively (Table 7).
Table 2: Treatments prescribed for osteoarthritis flare-ups
n % patients
COX2 NON-SELECTIVE NSAIDs
Arylacetic acid derivatives (diclofenac, indomethacin, sulindac, etc.) 221 16.7
Arylpropionic acid derivatives (ibuprofen, naproxen, ketoprofen, etc.) 165 12.5
Oxycams (piroxicam, tenoxicam, etc.) 181 13.7
Others (nabumetone, glucosamine, diacerein, etc.) 107 8.1
COX2 SELECTIVE NSAIDs
Nimesulide betadex (or nimesulide) 689 52.1
OTHER DRUGS/TREATMENTS
Various, systemic (ASA, paracetamol, corticosteroids, centrally acting myorelaxants) 46 3.5
Various, topical (transcutaneous or intraarticular) 44 3.3
Physical treatment (mobilization, iontophoresis, etc.) 60 4.5
Table 3: SF 36 scores (Mean ± SE). Baseline vs Follow-up scores. 
At the ANCOVAs: p < 0.001 for all domains
SF-36 domains Baseline Follow up p
Physical Functioning 47.9 ± 0.7 59.3 ± 0.7 <.001
Role Physical 27.8 ± 1.0 48.0 ± 1.1 <.001
Bodily Pain 31.7 ± 0.4 50.5 ± 0.5 <.001
General Health 45.8 ± 0.5 50.0 ± 0.5 <.001
Vitality 46.5 ± 0.5 53.2 ± 0.5 <.001
Social Functioning 44.1 ± 0.6 65.4 ± 0.6 <.001
Role Emotional 46.9 ± 1.2 65.7 ± 1.1 <.001
Mental Health 59.2 ± 0.5 65.4 ± 0.5 <.001Health and Quality of Life Outcomes 2005, 3:14 http://www.hqlo.com/content/3/1/14
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11.1% of patients reported side effects to medical treat-
ment of OA; most of these reactions involved the gastroin-
testinal system. Poor tolerability led to treatment
withdrawal in 6.2% of patients.
Discussion
Our study represents, to our knowledge, the largest obser-
vational prospective clinical trial carried out in OA
patients' subjective HRQoL. The sample size and the very
small number of drop-outs could be considered the
strenghts of the study.
A limit of the study could be considered the adoption of
the SAT-P which is a new questionnaire, validated on the
Italian population [30], but not previously used in clinical
trials or in OA patients. Nevertheless, its psychometric
properties have been previously confirmed, and moreover
it is the only Italian questionnaire specifically aimed at
assessing subjective satisfaction in daily life, independ-
ently of the presence of a disease. Its user friendly structure
and its easily comprehensible graphical representation
could be considered substantial methodological facilities
both in research and in clinical practice.
Finally, the coherence between the data provided by the
two HRQoL instruments could confirm that health status
and subjective satisfaction partially overlap, and allows us
to study the same phenomenon from two different points
of view: the objective and the subjective. This could there-
fore be considered the added value of the study.
Considering the whole sample, SF-36 results confirm
what previous studies have already enlightened in clinical
trials: the SF-36 is, according to Kosinski et al. [35], a suit-
Table 4: Detected statistical significances on SF-36 delta scores. The p values resulted from the ANCOVAs are indicated.
SF-36 domains Covariates
Age Gender Body weight OA localization Present Pain Concomitant diseases Treatment
Physical Functioning 0.021 0.0001 0.020
Role Physical 0.022 0.007
Bodily Pain 0.0001 0.0001 0.006
General Health 0.0001 0.003
Vitality 0.0001
Social Functioning 0.0001 0.003
Role Emotional 0.007
Mental Health 0.0001
Table 5: SAT-P factor scores (M ± SE). Baseline vs Follow-up scores. At the ANCOVAs: p < 0.001 for all Factors.
SAT-P Factors Baseline Follow up p
Psychological functioning 59.3 ± 0.6 65.5 ± 0.5 p <.001
Physical functioning 41.3 ± 0.5 51.9 ± 0.5 p <.001
Work 53.3 ± 0.7 57.8 ± 0.7 p <.001
Sleep/Eating/Leisure 55.4 ± 0.5 60.9 ± 0.5 p <.001
Social functioning 66.0 ± 0.6 70.8 ± 0.5 p <.001
Table 6: Detected statistical significances on SAT-P factors. The p values resulted from the ANCOVAs are indicated
SAT-P Factors Covariates
Age Gender Body weight OA localization Present Pain Concomitant diseases Treatment
Psychological functioning 0.0001 0.022
Physical functioning 0.0001
Work 0.007
Sleep/Eating/Leisure 0.0001 0.007 0.026
Social functioning 0.0001 0.018Health and Quality of Life Outcomes 2005, 3:14 http://www.hqlo.com/content/3/1/14
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able instrument for assessing health status in OA, and
medical treatment improves functionality levels in daily
life aspects.
The same conclusions could be drawn for the SAT-P: on
the whole sample a general improvement of satisfaction
levels can be observed in all the 32 items considered. In
other words, pharmacological treatment has a significant
SAT-P items: mean scores at baseline and at follow-up Figure 1
SAT-P items: mean scores at baseline and at follow-up. For all the differences (ANCOVAs) p < 0.001.
Table 7: OA treatments' evaluations (efficacy and tolerability)
Poor Moderate Good Excellent Missing data
n (%) n (%) n (%) n (%) n (%)
Efficacy – patients 163 (12.3) 288 (21.8) 634 (47.9) 227 (17.2) 11 (0.8)
Efficacy – physicians 129 (9.8) 292 (22.1) 634 (47.9) 257 (19.4) 11 (0.8)
Tolerability – patients 93 (7.1) 147 (11.1) 712 (53.8) 359 (27.1) 12 (0.9)
Tolerability – 
physicians
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positive impact on patients' both objective functioning
and subjective well-being [16].
Thanks to the sinergic utility of the two instruments it has
been possible to enlight results otherwise left unperceived
and whose positive value on patients' life is
unquestionable.
Further investigations are needed in order to better clarify
the relationships between perceived pain and pain relief
and patients' HRQoL. Mastery, self-efficacy and coping
abilities could be significant mediators between these two
constructs [38,39].
Conclusion
From both an objective and a subjective point of view, OA
flare-ups' treatment has proved to have positive effects on
HRQoL. The sinergic use of a health status measure (SF-
36) and of a tool addressing subjective satisfaction (SAT-
P) allows to wider the focus on patients' life.
This methodological approach could help clinicians and
researchers in transferring into practice the ICF model
issues [40], with special attention on Activity and Partici-
pation and on Environmental Factors.
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